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Abstract We performed a systematic review and meta-analysis of randomized placebo-controlled
trials that studied non-neurogenic overactive bladder patients who were treated with
100 units of onabotulinumtoxinA or placebo. The primary purpose of our study was to
evaluate the clinical effectiveness with regard to urinary urgency, urinary frequency,
nocturia, and incontinence episodes. Our secondary purpose consisted of evaluating the
adverse effects. Our initial search yielded 532 entries. Of these, seven studies met all the
inclusion criteria (prospective, randomized, placebo-controlled studies,  3 points on the
Jadad scale) and were selected for analysis. For all primary endpoints, the toxin was more
effective than placebo (p < 0.0001; 95% confidence interval [95CI]), namely: urgency
(mean difference ¼ -2.07; 95CI ¼ [-2.55–1.58]), voiding frequency (mean difference ¼ -
1.64; 95CI ¼ [-2.10–1.18]), nocturia (mean difference ¼ -0.25; 95CI ¼ [-0.39–0.11]) and
incontinence episodes (mean difference ¼ -2.06; 95CI¼ [-2.60–1.52]). The need for
intermittent catheterization and the occurrence of urinary tract infection (UTI) were
more frequent in patients treated with onabotulinumtoxinA than in patients treated with
placebo (p < 0.0001). Compared with placebo, onabotulinumtoxinA had significantly and
clinically relevant reductions in overactive bladder symptoms and is associated with higher
incidence of intermittent catheterization and UTI.
Resumo Realizou-se revisão sistemática emetanálise de estudos clínicos prospectivos, randomizados
e placebo-controlados que comparavam a toxina botulínica ao placebo no tratamento da
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Introduction
The International Continence Society defines overactive blad-
der as a syndrome characterized by urinary urgency, with or
without urgency urinary incontinence, usually accompanied
by nocturia and an increase in urinary frequency, in the
absence of infection, metabolic or local factors.1
Different population studies concluded that overactive
bladder is highly prevalent both in males and females, with
relevant negative impact on the patients’ quality of life (social,
physical, psychological, sexual, personal relationships, work,
and domestic domains); moreover, it has a considerable
financial impactonpatients themselves and thus on thehealth
care system.2–5
Patients who do not satisfactorily respond to behavioral
and/or pharmacological treatment are diagnosed with refrac-
tory overactive bladder. This group includes patients with
contraindications and intolerable side effects to medication.6
While both the European Association of Urology (EAU)
and the American Urological Association (AUA) recommend
intravesical injection of botulinum toxin A in refractory
overactive bladder cases, a vast majority of articles discusses
only neurogenic cases of this dysfunction.7,8
Our systematic review followed by meta-analysis includ-
ed only non-neurogenic overactive bladder patients who
were treated with 100 units of onabotulinumtoxinA.
Methods
Our study was registered in the PROSPERO database in 2016,
under the reference number CRD42016035815.
Prospective randomized placebo-controlled studies featur-
ing Jadad scalemethodological quality 3were selected.9 The
study populations should necessarily include patients aged
18 years or older with a diagnosis of non-neurogenic overac-
tive bladder syndrome treated with 100 units of onabotuli-
numtoxinA, at least in one of the arms of the study.
Patients with mixed urinary incontinence and a clear
prevalence of overactive bladder complaints were also includ-
ed. Performance of urodynamic study was not considered a
prerequisite for inclusion in our analysis, since overactive
bladder diagnosis is clinically suspected and detrusor overac-
tivity may or may not be present. The exclusion criteria
comprised use of a dose other than 100 units of onabotulinum
toxin A, use of botulinum toxin other than onabotulinumtox-
inA, neurogenic cases and literature or systematic reviews.
Primary Outcomes
The primary outcome of our study was to evaluate the
clinical effectiveness with regard to the following variables:
urgency (complaint of a sudden compelling desire to pass
urine that is difficult to defer),1urinary frequency (complaint
by the patient who considers that he/she voids too often by
day),1 nocturia (complaint that the individual has towake up
at night one or more times to void),1 and incontinence
episodes (complaint of any involuntary leakage of urine).1
Secondary Outcomes
The secondary outcome was to evaluate all adverse effects
reported in the studies included in the meta-analysis.
Study Search and Selection
We performed a search for randomized clinical trials (RCTs)
in the following electronic databases: Cochrane Central
Register of Controlled Trials (CENTRAL) and MEDLINE.
The MEDLINE search included the following terms: “over-
activebladder,” “detrusor overactivity,” “bladder overactivity,”
“botulinum toxin,” “onabotulinumtoxinA” and “botox.”
Only studies in English were selected, and the search was
done from the inception of the database, given that the use of
botulinumtoxin in the treatmentofnon-neurogenicoveractive
bladder is relatively recent. Two authors (R. M. A. and C. C. T.)
independently reviewedall the abstracts and titles to select the
papers that were relevant for review, later analyzing the full
bexiga hiperativa. O objetivo primário desta metanálise foi avaliar a eficácia da toxina
botulínica em relação à urgência urinária, frequência miccional, noctúria e episódios de
incontinência. O objetivo secundário foi avaliar os efeitos adversos. Selecionamos estudos
que incluíram somente pacientes com bexiga hiperativa não-neurogênica tratada com 100
unidades de onabotulinum toxina A ou placebo (grupo controle). Foram encontrados 532
estudos após as buscas iniciais, dos quais sete apresentaram todos os critérios de inclusão
(estudosprospectivos, randomizados, placebo-controlados,3pontosnaescalade Jadad) e
fizerampartedestaanálise. Para todososobjetivosprimários a toxina foimais eficazdoqueo
placebo, com p< 0,0001 e intervalo de confiança (IC) de 95%: urgência (diferençamédia¼
-2,07, IC¼ [-2,55; -1,58]), freqüênciamiccional (diferençamédia¼ -1,64, IC¼ [-2,10; -1,18]),
noctúria (diferençamédia¼ -0,25, IC¼ [-0,39; -0,11]) e episódiosde incontinência (diferença
média ¼ -2,06, IC¼ [-2,60; -1,52]). A necessidade de cateterização intermitente e a
ocorrência de infecção urinária (ITU) forammais frequentes no grupo toxina na comparação
com o grupo placebo (p< 0,0001). A toxina botulínica promoveu melhora significativa dos
sintomas de bexiga hiperativa na comparação com o placebo. Entretanto, está associada a
uma maior incidência de cateterismo intermitente e infecção do trato urinário.
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text of the selected studies to determine eligibility. The last
online searchwasperformedon June 20th, 2015. A spreadsheet
for data collectionwas created to extract the data of interest in
each article, which were then retyped in a single database to
avoid loss of data or mistyping of any kind. Any disagreements
were resolved by consulting a third author (R. A. C.). Outcomes
verified in two articles or more were grouped for meta-
analysis.
Statistical Analysis
We summarized binary outcomes based on the number of
events using Peto odds ratio in situations with zero number of
events in one of the groups, or theMantel-Haenszelmethod in
situations of a very low event rate. Furthermore, we summa-
rized continuous outcomes (incontinence, urgency, frequency
and nocturia) using the mean difference (MD), calculated by
the inverse variance method. Precision of estimates appear as
95% confidence intervals (95CIs).
Heterogeneity across studies was evaluated using
CochranQ statistic andHiggins I2.10Wequantified statistical
heterogeneity using I2, informing its value together with the
estimates.We considered I2 elevatedwhenever it was higher
than 60%. However, a fixed-effect model was considered
when a very small number of studies were included.10
In addition to the heterogeneity analyses described above,
sensitivity analyses excluding one study at a time were
performed to evaluate the influence of individual studies
on the overall result. We used the RevMan 5.3 statistical
package (Nordic Cochrane Center, Copenhagen, Denmark) to
perform the analysis.
Quality Assessment
The quality of studies included in the analysis was indepen-
dently assessed by two authors (R. M. A. and C. C. T.) using the
Jadad scale for RCTs classification.9 Studies scoring  3 were
considered eligible for inclusion. Any disagreements were
resolved by consulting a third author (R. A. C.).
The Jadad scale assesses the quality of published clinical
trials based on methods relevant to random assignment,
double blinding, and patient flow. There are seven items,
but points may be deducted in the last two, which means
that the range of possible scores is 0 (bad) to 5 (good).9 Thebias
risk was assessed by the use of a Cochrane collaboration tool.1
Results
Description of Studies
►Fig. 1 describes the flowchart for this review. Five hundred
and thirty-two articles were retrieved after research on the
Cochrane and Medline databases, using the keywords “over-
active bladder” OR, “detrusor overactivity” OR “bladder
overactivity” AND “botulinum toxin” OR “onabotulinumtox-
inA” OR “botox.”
Out of those, 333 articles were selected after reading the
title and abstract, whereas 271 were excluded since they did
not meet selection criteria. Therefore, 62 articles were consid-
ered eligible and read in full by two authors. After this initial
reading, 53 articleswere excluded for using onabotulinumtox-
inB and/or for including patients with neurogenic overactive
bladder. Eventually, 9 studiesmet all the inclusion criteria and
were selected for this meta-analysis (►Fig. 1 and ►Table 1)
Fig. 1 Flow diagram of article selection.
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Two studies could be included for analysis of urinary urgen-
cy, urinary frequency, nocturia, and incontinence episodes.
There was no evidence of heterogeneity among the articles,
except for urinary incontinence. However, because the number
of articles is very small, the fixed-effect model was considered.
It can be observed in ►Fig. 2 that there was significant
reduction in urinary urgency episodes in the toxin group
(experimental group) in comparison with the placebo group
(control group) (MD ¼ -2.07, 95CI ¼ [-2.55; -1.58];
p < 0.0001).
►Fig. 3 shows that there was significant reduction in
urinary frequency in the toxin group (experimental group)
when compared with the placebo group (control group)
(MD ¼ -1.64, 95CI ¼ [-2.10; -1.18]; p < 0.0001).
A similar result was observed in analyzing nocturia epi-
sodes (►Fig. 4). There was significant reduction in nocturia in
the toxingroup (experimentalgroup) in relation to theplacebo
group (control group) (MD ¼ -0.25, 95CI ¼ [-0.39; -0.11];
p < 0.0001).
In ►Fig. 5 we further confirmed that there was significant
reduction in the number of urinary incontinence episodes in
the toxingroup (experimentalgroup) in relation to theplacebo
group (control group) (MD ¼ -2.06, 95CI ¼ [-2.60; -1.52];
p < 0.0001).
Secondary Purposes
Adverse Effects of Catheterization
For analysis of vesical catheterization occurrence, it was
possible to include five studies. According to the data
(►Fig. 6), it is possible to verify that the need for catheteriza-
tionwas significantly higher in the toxin group (experimental
Fig. 4 Forest plot of change in nocturia episodes after onabotulinumtoxinA (experimental) and placebo (control) injections.
Table 1 Articles included in the meta-analysis
References Study design Jadad scale N placebo/toxin Weeks follow-up
Chapple et al.11 Multicenter, randomized, double-blind 5 271/277 12
Denys et al.12 Multicenter, randomized, double-blind 5 29/70 24
Dmochowski et al.13 Multicenter, randomized, double-blind 5 43/268 36
Dowson et al.14 Single-center, randomized, double-blind 5 11/10 24
Flynn et al.15 Single-center, randomized, double-blind 5 7/15 6
Nitti et al.16 Multicenter, randomized, double-blind 5 44/54 36
Rovner et al.17 Multicenter, randomized, double-blind 5 44/269 36
Fig. 3 Forest plot of change in frequency after onabotulinumtoxinA (experimental) and placebo (control) injections.
Fig. 2 Forest plot of change in urgency after onabotulinumtoxinA (experimental) and placebo (control) injections.
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group) when compared with the placebo group (control
group), with no heterogeneity in this analysis.
In ►Fig. 7 we present the forest plot graph for the data
referring to urinary tract infection occurrence. We note in
the plot forest graph that the Peto odds ratio meta-analytical
value (OR ¼ 2.69, IC (95%) ¼ [1.83; 3.97]; p value < 0.0001)
is located fully to the right of the vertical line. Such result
demonstrates higher probability of urinary infection in the
toxin group (experimental) when compared with the place-
bo group (control). Homogeneity among studies was con-
firmed by Q (Chi) in the Cochran test (p value ¼ 0.25).
Regarding the quality of life evaluation, it was not possible
to perform themeta-analysis, since the authors used different
questionnaires,whichmade it impossible toevaluate this item.
Discussion
Our results demonstrated that the onabotulinumtoxinA had
greater efficiency when compared with the placebo in rela-
tion to the all the symptoms analyzed (urinary frequency,
nocturia, and urinary incontinence episodes). Such results
are also in agreement with other systematic reviews and
meta-analyses in respect to the subject.18,19
There was significant reduction in the number of urinary
urgency episodes in the group treated with toxin in compar-
ison with the placebo group. However, none of the studies
evaluated urgency intensity, probably because it is a subjec-
tive symptom, and it is very difficult to be characterized.
The last Cochrane review (2011)19 on this topic included
19 studies, mostly with neurogenic patients. In our study, we
were interested in demonstrating the efficacy of onabotuli-
numtoxinA in the treatment of non-neurogenic overactive
bladder, which is usually followed by the gynecologist.
We chose to include only articles in which the toxin used
was onabotulinumtoxinA because it is the toxin most fre-
quently indicated in Brazil, and it is available to treat
overactive bladder in both private and public health services.
Although most studies included analyzed the patients’
quality of life, unfortunately it was not possible to perform a
systematic reviewof this variable given that the authors used
different tools for this evaluation. Nevertheless, different
studies have concluded that botulinum toxin significantly
improves patient symptoms and quality of life.11,20
In the articles included in our study, the only side effects
significantly higher in the toxin group in comparison with the
placebowereurinary tract infectionandurinary retention. Such
Fig. 5 Forest plot of change in urinary incontinence episodes after onabotulinumtoxinA (experimental) and placebo (control) injections.
Fig. 6 Forest plot of change of pulmonary vascular resistance-related catheterization after 100 units of onabotulinumtoxinA (experimental) and
placebo (control) injections.
Fig. 7 Forest plot of change of urinary tract infection after 100 units of onabotulinumtoxinA (experimental) and placebo (control) injections.
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side effects were both more frequent in the 100 units dose.
Furthermore, other possible side effects are dry mouth, hema-
turia, respiratorydepression, andgeneralmuscularweakness.21
Urinary retention was the main complication reported in
the studies. According to the literature data, its incidence
ranges from 0–72%, depending on the toxin dose used and
the definition of urinary retention with or without need for
catheterization (which is extremely variable among the
authors).19,20 Most articles included in this meta-analysis
considered as urinary retention the presence of post-urina-
tion residue  200 mL.11–13,17
The need for intermittent catheterization at the 100 units
dose, which is the most frequently used dosage in non-
neurogenic cases, ranged from 6.911–30%.14
It should be noted, however, that the indication of cathe-
terizationwasvariedamong the studies. Thelowest ratewas in
Chapple et al,11which only indicated it in asymptomatic cases
if post-urination residuewas  350mL. In turn, Brubaker et al
(2008)21 indicated intermittent catheterization in cases with
post-urination residue > 200 mL after 4 weeks from the
injection, regardless of the symptoms. Such differences be-
tween the definitions for urinary retention and the need for
catheterization render comparison among studies difficult. In
addition, possible clinical consequences of asymptomatic uri-
nary retention are not clear. Regardless, such retention is
transitory and dose-dependent.11,20,22
The primary strength of this systematic review was to
only include prospective, randomized, placebo-controlled
articles featuring Jadad scale methodological quality  than
3.9 The fact that we have only included patients treated
with 100 units of onabotulinumtoxinA and non-neurogenic
cases also contributed to facilitate the interpretation of
results.
The limitations refer mainly to the differences between
injection application techniques, the follow-up time, and the
evaluation of quality of life, which undoubtedly renders
greater generalization of results.
Conclusion
In comparison with the placebo, onabotulinumtoxinA pro-
motes significant improvement of urinary urgency, urinary
frequency, nocturia, and incontinence symptoms. There is
higher incidence of urinary retention and urinary tract infec-
tion among patients in the toxin group in relation with the
placebo group. It was not possible to evaluate the effects on
quality of life. This systematic review is endorsed by the
Urogynecology Committee of the Federação das Associações
BrasileirasdeGinecologia eObstetrícia (BrazilianFederationof
the Societies of Gynecology and Obstetrics, [FEBRASGO, in the
Portuguese acronym]) and suggests that the dose of 100 units
of onabotulinumtoxinA is effective in the treatment of non-
neurogenic refractory overactive bladder.
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